Is the New York Times a Shill for Promoters of Psychedelics?

Evidence that the newspaper is not sufficiently detached from promoters to provide an open-minded but skeptical perspective that readers should be able to expect.

Exponential Innovation: Disrupting The Disruptor

Today's world of disruptive change is defined by two terms: innovation and speed.  The big idea is important, but equally so is the path that innovation...

Psilocybin as an Antidepressant for Cancer Patients Who Are Not Depressed

Research concerning the role of psychedelics in mental health treatment and its superb publicity campaign depends on millions of dollars raised by venture capitalists.

Blaming the Psychiatric Patient When It’s a Drug-Genetic Interaction

How can patients with psychiatric or any other illnesses be viewed as non-compliant with their medical regimes when there is a persistent failure to investigate how their race and genetics are affecting treatment